skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence

Journal Article · · Proceedings of the National Academy of Sciences of the United States of America
 [1];  [2];  [2];  [2]; ORCiD logo [3];  [4]; ORCiD logo [5];  [6];  [2];  [2];  [7]
  1. Department of Mathematics, North Carolina State University, Raleigh, NC 27695,, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545,
  2. Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104,, Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104,
  3. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545,, Laboratory of Biomathematics, Faculty of Medicine, University of Lisbon, 1600-276 Lisbon, Portugal,
  4. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545,
  5. Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545,, Santa Fe Institute, Santa Fe, NM 87501,
  6. Department of Infectious Disease, Merck &, Co., Inc., Kenilworth, NJ 07033
  7. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545,, Santa Fe Institute, Santa Fe, NM 87501,

RNA viruses exist as a genetically diverse quasispecies with extraordinary ability to adapt to abrupt changes in the host environment. However, the molecular mechanisms that contribute to their rapid adaptation and persistence in vivo are not well studied. Here, we probe hepatitis C virus (HCV) persistence by analyzing clinical samples taken from subjects who were treated with a second-generation HCV protease inhibitor. Frequent longitudinal viral load determinations and large-scale single-genome sequence analyses revealed rapid antiviral resistance development, and surprisingly, dynamic turnover of dominant drug-resistant mutant populations long after treatment cessation. We fitted mathematical models to both the viral load and the viral sequencing data, and the results provided strong support for the critical roles that superinfection and cure of infected cells play in facilitating the rapid turnover and persistence of viral populations. More broadly, our results highlight the importance of considering viral dynamics and competition at the intracellular level in understanding rapid viral adaptation. Thus, we propose a theoretical framework integrating viral and molecular mechanisms to explain rapid viral evolution, resistance, and persistence despite antiviral treatment and host immune responses.

Research Organization:
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States); Santa Fe Inst. (SFI), Santa Fe, NM (United States); Univ. of Pennsylvania, Philadelphia, PA (United States)
Sponsoring Organization:
USDOE; National Inst. of Health (NIH) (United States)
Grant/Contract Number:
AC52-06NA25396; R01-OD011095; R01-AI028433; R01-AI078881; R01-AI116868; U19-AI088791; P30-AI45008
OSTI ID:
1459484
Alternate ID(s):
OSTI ID: 1625021
Journal Information:
Proceedings of the National Academy of Sciences of the United States of America, Journal Name: Proceedings of the National Academy of Sciences of the United States of America Vol. 115 Journal Issue: 30; ISSN 0027-8424
Publisher:
Proceedings of the National Academy of SciencesCopyright Statement
Country of Publication:
United States
Language:
English
Citation Metrics:
Cited by: 11 works
Citation information provided by
Web of Science

References (58)

Unifying the Epidemiological and Evolutionary Dynamics of Pathogens journal January 2004
Analysis of Hepatitis C Virus Superinfection Exclusion by Using Novel Fluorochrome Gene-Tagged Viral Genomes journal February 2007
Characterization of Hepatitis C Virus Recombination in Cameroon by Use of Nonspecific Next-Generation Sequencing journal July 2015
The role of mutational robustness in RNA virus evolution journal March 2013
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial journal March 2015
Superinfection Exclusion in Cells Infected with Hepatitis C Virus journal February 2007
A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure journal May 2010
Influence of Viral Replication Mechanisms on Within-Host Evolutionary Dynamics: Influence of Viral Replication Mechanisms on Within-Host Evolutionary Dynamics journal June 2012
Evasion of Superinfection Exclusion and Elimination of Primary Viral RNA by an Adapted Strain of Hepatitis C Virus journal October 2013
Viral Quasispecies Evolution journal June 2012
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: Implications for treatment duration journal May 2011
Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver journal April 2014
Mathematical Analysis of HIV-1 Dynamics in Vivo journal January 1999
The role of cells refractory to productive infection in acute hepatitis B viral dynamics journal March 2007
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations journal December 2011
MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants journal May 2012
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus journal May 2010
Vacated niches, competitive release and the community ecology of pathogen eradication journal August 2013
In vitro combinations containing Tegobuvir are highly efficient in curing cells from HCV replicon and in delaying/preventing the development of drug resistance journal August 2015
Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration journal October 2013
Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing journal August 2012
Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate journal August 2012
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection journal May 2008
Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes journal November 2014
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants journal April 2010
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs journal December 2002
Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells journal November 2004
Viral and Cellular Determinants of Hepatitis C Virus RNA Replication in Cell Culture journal March 2003
Low Dynamic State of Viral Competition in a Chronic Avian Hepadnavirus Infection journal June 2000
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study journal October 2016
Highly Permissive Cell Lines for Subgenomic and Genomic Hepatitis C Virus RNA Replication journal December 2002
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection journal December 2015
Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance journal May 2017
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus journal February 2011
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin journal December 2014
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy journal October 1998
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life journal February 2013
Analysis of Hepatitis C Virus Decline during Treatment with the Protease Inhibitor Danoprevir Using a Multiscale Model journal March 2013
Pre–existence and emergence of drug resistance in HIV–1 infection journal May 1997
Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics journal December 2010
Antibody neutralization and escape by HIV-1 journal March 2003
Genetic recombination of the hepatitis C virus: clinical implications: Impacts of HCV recombination journal September 2010
Quantification of Hepatitis C Virus Cell-to-Cell Spread Using a Stochastic Modeling Approach journal April 2015
Avoiding the void: cell-to-cell spread of human viruses journal November 2008
The Outcome of Hepatitis C Virus Infection Is Predicted by Escape Mutations in Epitopes Targeted by Cytotoxic T Lymphocytes journal December 2001
Modeling Viral Spread journal September 2016
Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection journal June 2015
A perspective on modelling hepatitis C virus infection: A perspective on modelling HCV infection journal August 2010
Beneficial Mutation–Selection Balance and the Effect of Linkage on Positive Selection journal May 2007
Pre-existence and emergence of drug resistance in a generalized model of intra-host viral dynamics journal December 2012
Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection journal September 2014
Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4 journal February 2015
Evolutionary Analysis of Human Immunodeficiency Virus Type 1 Therapies Based on Conditionally Replicating Vectors journal October 2012
Influenza A Virus Uses Intercellular Connections To Spread to Neighboring Cells journal November 2014
Antiretroviral dynamics determines HIV evolution and predicts therapy outcome journal September 2012
Use of Laser Capture Microdissection to Map Hepatitis C Virus–Positive Hepatocytes in Human Liver journal December 2013
Global control of hepatitis C: where challenge meets opportunity journal July 2013
Origin and Evolution of the Unique Hepatitis C Virus Circulating Recombinant Form 2k/1b journal November 2011